c106
Safety Issues
Vicore Pharma ABPhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
17 Active assets in the Safety Issues cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
mb07133 Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Phase 2 | B |
Remifemin Zhejiang Cancer Hospital | Phase 2 | B |
Irinotecan Assiut University | Phase 2 | B |
(+)-VINCRISTINE Assiut University | Phase 2 | B |
Nivolumab Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 | CCC |
View all 26 →
Same molecule, other indications
c106 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →